Tatva Chintan Pharma
IPO Size
`500 Cr
Price Band
`1073-1083 Per Share
Minimum Lot Size
13 Share
Face Value
`10 Per Share
Employee Discount
NA
Retail Allocation
35%
Issue Open Date
16 July, 21
Issue Close Date
20 July, 21
Listing Date
IPO Size
Price Band
Minimum Lot Size
Face Value
Employee Discount
Retail Allocation
Issue Open Date
Issue Close Date
Listing Date
About the Company:
Tatve Chintan Pharma is a specialty chemicals manufacturing company which is engaged in the manufacturing of a diverse portfolio of structure directing agents, phase transfer catalysts, electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals. As a B2B platform, the company focuses on application of their products which form a key ingredient for their customers’ manufacturing and industrial processes. SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies.
Considering the wide application of products, the company serves customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries. Apart from our customers in India, Tatva Chintan is an also exporter to over 25 countries, including the USA, China, Germany, Japan, South Africa, and the UK.
Outstanding Litigation:
| S.No. | 1 - Company | 2 - Promoters | 3 - Directors | |||
| Entity Name | By the Company | Against the Company | By the Promoters | Against the Promoters | By the Subsidiaries | Against the Subsidiaries |
| Criminal cases | 2 | - | - | 1 | - | 1 |
| Material civil cases | - | - | - | - | - | - |
| Taxation matters | - | 2 | - | - | - | - |
| Regulatory Procedings | - | - | - | - | - | - |
| Amt. (In Million Rs.) | 0.78 | 19.16 | - | Non-Quantifiable | - | Non-Quantifiable |
Financial Statements:
| Income Statement (In Millions) | FY21 | FY20 | FY19 | FY18 | |
| Gross Operating Income | 3062.92 | 2646.22 | 2068.01 | 4045.63 | |
| Cost of Employee & Inventory | 1735.23 | 1532.96 | 1305.54 | 2904.93 | |
| Other Expenses | 611.34 | 549.91 | 419.51 | 2679.75 | |
| EBITDA | 716.35 | 563.35 | 342.96 | -1539.05 | |
| Depreciation | 67.32 | 47.93 | 40.18 | 291.47 | |
| Interest | 42.07 | 39.45 | 36.34 | 63.49 | |
| Exceptional Items | - | - | 7.49 | - | |
| Profit Before Tax | 606.96 | 475.97 | 273.93 | -1894.01 | |
| Tax | 84.34 | 98.08 | 68.5 | - | |
| Profit After Tax | 522.62 | 475.97 | 205.43 | -1894.01 | |
The promoters of the company are Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Snehkar Rasiklal Somani.
The company will face tough competition from PI Industries, Aarti Industries, Navin Fluorine, Atul Limited, Fine Organics, Alkyl Amines and SRF Limited.
The object of the Offer for Sale is to allow the shareholders to sell an aggregate of up to 25,39,242 equity Shares held by them. The company will not receive any proceeds from the Offer for Sale.
The company has planned to raise fresh capital comprising an aggregate of 20,77,562 equity shares having Face Value ₹10 aggregating up to Rs. 225 Cr at the upper price band of Rs. 1,083. Out of the net proceeds • An amount of Rs. 147.10 cr. will be allocated for capital expenditure requirements to expand the Dahej Manufacturing Facility • An amount of Rs. 23.97 cr. will be utilized for upgradation at R&D facility in Vadodara. • Rest will be utilized for general corporate purpose.